The drug makers, along with three other pharma companies, made their official disclosures on the Dhaka Stock Exchange’s (DSE) website on the day
Two largest listed pharmaceutical companies — Square and Beximco — yesterday reported higher earnings per share (EPS) in the first six months of the current fiscal year amid a dull investment regime in the local economy.
The drug makers, along with three other pharma companies, made their official disclosures on the Dhaka Stock Exchange’s (DSE) website on the day.
Explaining the reasons behind this profit growth in the pharmaceutical sector, the sector insiders said that growing per capita income, population growth, rise in life expectancy, changing disease profile, lifestyle change and rapid urbanization were the key contributors.
Besides, new investments as well as the inclusion of modern technology increased the production capacity in the sector, they added.
According to the un-audited report of Square Pharmaceuticals Ltd, the consolidated half yearly (July-December’19) EPS was Tk8.16 against Tk7.46 for the same period of previous year.
Besides, the company’s consolidated EPS was Tk4.18 for October-December’19 (second quarter) against Tk3.70 for the same period last year.
Each share of Square Pharma dropped by 0.40%, closing at Tk197.40 on the day. The company’s paid-up capital is Tk844 crore.
As per Beximco Pharmaceuticals Limited’s disclosure, the company’s consolidated EPS was Tk4.26 for the first six months of current fiscal year against Tk3.67 for the same period of previous year. In October-December 2019, the company’s EPS was Tk2.12 against Tk1.81 for October-December 2018.
The share price of the drug company closed at Tk72.50. The company’s paid-up capital is Tk405 crore.
Besides the two leading drug makers, Renata Limited has also reported higher EPS of Tk22.45 for the given period against Tk19.16 for July-December’18. The company’s earnings per share was Tk10.83 for second quarter (October-December’19) as against Tk9.65 for same period of the previous year.
According to Export Promotion Bureau (EPB) data, Bangladesh’s medicine exports registered a 25.60% rise to $130 million in FY19, which was $103.46 million the previous year.
Meanwhile, Acme Laboratories Limited’s reported lower EPS on the same day compared to the same period of previous year.
According to the un-audited report of Acme Laboratories, the EPS was Tk3.66 for July-December’19 as against Tk3.69 for same period of 2018 year. Earnings per share was Tk1.77 for three months (October-December’19) as against Tk1.85 for same period of previous year.
As per the Ambee Pharmaceuticals Limited disclosure, the company’s EPS was Tk1.63 against Tk1.69 for the same period of last year.
The EPS is the company's profit allocated to each share of a listed firm, indicating a company's profitability.
However, analysts have said the unaudited EPS of a company often does not reflect actual financial health of a listed firm, but indicates profitability that influences investors towards their long-term investment plans.